Hill-Rom Holdings, Inc. (NYSE:HRC) Receives $121.40 Consensus PT from Analysts

Shares of Hill-Rom Holdings, Inc. (NYSE:HRC) have been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $121.40.

Separately, Morgan Stanley raised shares of Hill-Rom from an “equal” rating to an “equal weight” rating and increased their target price for the stock from $113.00 to $138.00 in a research note on Tuesday, December 17th.

In other Hill-Rom news, SVP Andreas G. Frank sold 6,000 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $105.83, for a total transaction of $634,980.00. Following the completion of the transaction, the senior vice president now directly owns 40,004 shares in the company, valued at $4,233,623.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Deborah Rasin sold 4,739 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $103.97, for a total transaction of $492,713.83. Following the transaction, the senior vice president now owns 31,001 shares of the company’s stock, valued at $3,223,173.97. The disclosure for this sale can be found here. 0.73% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in HRC. BlackRock Inc. boosted its position in Hill-Rom by 4.9% during the second quarter. BlackRock Inc. now owns 6,649,313 shares of the medical technology company’s stock worth $695,650,000 after acquiring an additional 307,825 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Hill-Rom by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 6,322,476 shares of the medical technology company’s stock worth $661,458,000 after purchasing an additional 163,177 shares during the last quarter. Select Equity Group L.P. increased its position in shares of Hill-Rom by 79.9% during the 3rd quarter. Select Equity Group L.P. now owns 2,556,189 shares of the medical technology company’s stock worth $268,988,000 after purchasing an additional 1,135,168 shares during the last quarter. Invesco Ltd. raised its holdings in Hill-Rom by 3.9% in the 2nd quarter. Invesco Ltd. now owns 1,120,793 shares of the medical technology company’s stock valued at $117,257,000 after buying an additional 42,163 shares during the period. Finally, Northern Trust Corp raised its holdings in Hill-Rom by 1.3% in the 2nd quarter. Northern Trust Corp now owns 662,405 shares of the medical technology company’s stock valued at $69,300,000 after buying an additional 8,267 shares during the period. Institutional investors and hedge funds own 82.78% of the company’s stock.

Shares of HRC traded down $0.59 during trading hours on Friday, hitting $115.75. The stock had a trading volume of 386,888 shares, compared to its average volume of 272,146. The firm has a 50-day moving average price of $111.79 and a 200 day moving average price of $106.32. Hill-Rom has a fifty-two week low of $93.88 and a fifty-two week high of $117.10. The firm has a market capitalization of $7.79 billion, a price-to-earnings ratio of 51.44, a PEG ratio of 1.80 and a beta of 0.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.10 and a current ratio of 1.31.

Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, November 1st. The medical technology company reported $1.69 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.65 by $0.04. Hill-Rom had a net margin of 5.24% and a return on equity of 21.67%. The company had revenue of $782.80 million for the quarter, compared to analyst estimates of $759.14 million. During the same quarter last year, the business earned $1.63 earnings per share. The firm’s revenue was up 3.1% on a year-over-year basis. As a group, analysts predict that Hill-Rom will post 5.53 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 16th were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.73%. The ex-dividend date was Friday, December 13th. Hill-Rom’s payout ratio is currently 16.54%.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

See Also: Swap

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.